Description…

YWHAQ, also known as 14-3-3 theta, belongs to the 14-3-3 family of proteins which mediate signal transduction by binding to phosphoserine-containing proteins. This highly conserved protein family is found in both plants and mammals, and this protein is 99% identical to the mouse and rat orthologs. The 14-3-3 proteins have a wide range of ligands, are involved in a variety of biological pathways, and are known to be overexpressed in some human lung cancers, suggesting that they may play a role in tumorigenesis. 14-3-3 theta is an adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathway. It binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. 14-3-3 theta antigens have been found to be targets of autoantibodies in subjects newly diagnosed with lung cancer.

Attributes

QA State:

Accepted

Type:

Protein

Short Name:

HGNC Name:

YWHAQ

Datasets

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase:

Three

QA State:

Under Review

Overview

14-3-3 theta, previously found to be the target of autoantibodies in newly diagnosed subjects with lung cancer, is also associated with autoantibodies in sera collected at the pre-symptomatic stage. These findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens, including 14-3-3 theta.

Performance Comment

The findings of this study suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens. Investigation of 14-3-3 theta is ongoing.

Supporting Study Data

The following studies/protocols provide evidence supporting
YWHAQ
indications for the
Lung…

Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status.
1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody.
1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.